Raquel Girardello

Dr. Raquel Girardello

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2022 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
CACarlos Henrique Alves
Carlos Henrique Alves
KRKarolayne Larissa Russi
Karolayne Larissa Russi
NRNatália Conceição Rocha
Natália Conceição Rocha
FBFábio Bastos
Fábio Bastos
MDMichelle Darrieux
Michelle Darrieux
RGRaquel Girardello
Raquel Girardello
In the last decades, the ortho-aesthetic-functional rehabilitation had significant advances with the advent of implantology. Despite the success in implantology surgeries, there is a percentage of failures mainly due to in loco infections, through bacterial proliferation, presence of fungi and biofilm formation, originating peri-implantitis. In this sense, several studies have been conducted since then, seeking answers to numerous questions that remain unknown. Thus, the present work aims to discuss the interaction between host-oral microbiome and the development of peri-implantitis. Peri-implantitis was associated with a diversity of bacterial species, being Porphiromonas gingivalis, Treponema denticola and Tannerella forsythia described in higher proportion of peri-implantitis samples. In a parallel role, the injury of peri-implant tissue causes an inflammatory response mediated by activation of innate immune cells such as macrophages, dendritic cells, mast cells, and neutrophils. In summary, the host immune system activation may lead to imbalance of oral microbiota, and, in turn, the oral microbiota dysbiosis is reported leading to cytokines, chemokines, prostaglandins, and proteolytic enzymes production. These biological processes may be responsible for implant loss.

1 July 2012 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
RGRaquel Girardello
Raquel Girardello
PPaulo Bispo
Paulo Bispo
TYTiago M. Yamanaka
Tiago M. Yamanaka
AGAna Cristina Gales
Ana Cristina Gales
Polymyxins have been the only alternative therapeutic option for the treatment of serious infections caused by multidrug-resistant Acinetobacter baumannii or Pseudomonas aeruginosa isolates. For this reason, it is of crucial importance that susceptibility tests provide accurate results when testing these drug-pathogen combinations. In this study, the effect of cation concentration variability found on different commercial brands of Mueller-Hinton agar (MHA) for testing polymyxin B susceptibility was evaluated. The polymyxin B susceptibilities determined using Etest and disk diffusion were compared to those determined by the CLSI reference broth microdilution method. In general, the polymyxin B MIC values were higher when determined by Etest than when determined by broth microdilution against both A. baumannii and P. aeruginosa isolates. A high very major error rate (10%) was observed, as well as a trend toward lower MICs, compared to those determined by broth microdilution when the Merck MHA was tested by Etest. Poor essential agreement rates (10 to 70%) were observed for P. aeruginosa when all MHA brands were tested by Etest. Although an excellent categorical agreement rate (100%) was seen between the disk diffusion and broth microdilution methods for P. aeruginosa , larger zones of inhibition were shown obtained using the Merck MHA. The high cation concentration variability found for the MHA brands tested correlated to the low accuracy, and discrepancies in the polymyxin B MICs were determined by Etest method, particularly for P. aeruginosa isolates.

25 October 2016 in BMC Genomics
Verified
Journal Article
Open access
PDF file
PRPablo Ivan Pereira Ramos
Pablo Ivan Pereira Ramos
MCMárlon Grégori Flores Custódio
Márlon Grégori Flores Custódio
GSGuadalupe del Rosario Quispe Saji
Guadalupe del Rosario Quispe Saji
TCThiago Cardoso
Thiago Cardoso
GSGisele Lucchetti da Silva
Gisele Lucchetti da Silva
Marisa FABIANA NICOLÁSMarisa FABIANA NICOLÁS
Marisa FABIANA NICOLÁS
The emergence of multidrug-resistant Klebsiella pneumoniae is a major public health concern. Many K. pneumoniae infections can only be treated when resorting to last-line drugs such as polymyxin B (PB). However, resistance to this antibiotic is also observed, although insufficient information is described on its mode of action as well as the mechanisms used by resistant bacteria to evade its effects. We aimed to study PB resistance and the influence of abiotic stresses in a clinical K. pneumoniae strain using whole transcriptome profiling. We sequenced 12 cDNA libraries of K. pneumoniae Kp13 bacteria, from two biological replicates of the original strain Kp13 (Kp13) and five derivative strains: induced high-level PB resistance in acidic pH (Kp13pH), magnesium deprivation (Kp13Mg), high concentrations of calcium (Kp13Ca) and iron (Kp13Fe), and a control condition with PB (Kp13PolB). Our results show the involvement of multiple regulatory loci that differentially respond to each condition as well as a shared gene expression response elicited by PB treatment, and indicate the participation of two-regulatory components such as ArcA-ArcB, which could be involved in re-routing the K. pneumoniae metabolism following PB treatment. Modules of co-expressed genes could be determined, which correlated to growth in acid stress and PB exposure. We hypothesize that polymyxin B induces metabolic shifts in K. pneumoniae that could relate to surviving against the action of this antibiotic. We obtained whole transcriptome data for K. pneumoniae under different environmental conditions and PB treatment. Our results supports the notion that the K. pneumoniae response to PB exposure goes beyond damaged membrane reconstruction and involves recruitment of multiple gene modules and intracellular targets.

7 October 2016 in Diagnostic Microbiology and Infectious Disease
Verified
Journal Article
Closed access
PDF file
RGRaquel Girardello
Raquel Girardello
MVMarina Visconde
Marina Visconde
RCRodrigo Cayô
Rodrigo Cayô
RFRegina Celia Bressan Queiroz Figueiredo
Regina Celia Bressan Queiroz Figueiredo
MMMarcelo Alves da Silva Mori
Marcelo Alves da Silva Mori
AGAna Cristina Gales
Ana Cristina Gales

1 August 2018 in Diagnostic Microbiology and Infectious Disease
Verified
Journal Article
Closed access
RGRaquel Girardello
Raquel Girardello
ACAna Paula Cury
Ana Paula Cury
MFMaria Renata Gomes Franco
Maria Renata Gomes Franco
TGThais Romano Di Gióia
Thais Romano Di Gióia
JAJoão Nóbrega de Almeida
João Nóbrega de Almeida
FRFlavia Rossi
Flavia Rossi

11 March 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
LALucas Assoni
Lucas Assoni
ICIsabelle Ciaparin
Isabelle Ciaparin
MTMonalisa Martins Trentini
Monalisa Martins Trentini
JBJuliana Baboghlian
Juliana Baboghlian
GRGabriel Rodrigo
Gabriel Rodrigo
MDMichelle Darrieux
Michelle Darrieux
Background: Klebsiella pneumoniae infections pose a great burden worldwide, causing high morbidity and mortality, which are worsened by the increase in multidrug-resistant strains. New therapeutic/prophylactic strategies are urgently needed to overcome antibiotic resistance and reduce the health and economic impacts of diseases caused by this pathogen. Fimbriae are important virulence factors involved in biofilm formation and adhesion to host cells. Their exposed location, conservation among clinical isolates and adjuvant properties make them interesting candidates for inclusion in protein-based vaccines. Therefore, the present work investigated the immunological potential of type 1 and 3 fimbriae subunits in a murine model of K. pneumoniae lung infection. Methods: MrkA and FimA were produced as recombinant proteins in E. coli, purified and used to immunize mice subcutaneously. The immune responses were characterized and protection against pneumonia was evaluated after intranasal challenge. Results: Subcutaneous immunization with recombinant FimA and MrkA induced high IgG1 production; the antibodies efficiently recognized the native proteins at the bacterial surface, promoted C3 deposition and reduced biofilm formation by K. pneumoniae in vitro. Mice vaccinated with the co-administered proteins reduced the bacterial loads in the lungs after intranasal challenge, less inflammation and reduced tissue damage. Conclusion: The results suggest that both type 1 and type 3 fimbriae contribute to protection against K. pneumoniae lung infection, inducing antibodies that bind to the bacteria and favoring Complement deposition and clearance by the host, while inhibiting biofilm formation.